文献速递急性肾损伤慢性肾脏病

重组α-Klotho对急性至慢性肾脏病进展及尿毒症性心肌病可能具有预防和治疗作用

Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
PubMed 文献 · Kidney Int · 2017-01-25

本文探讨重组α-Klotho对急性肾损伤后向慢性肾脏病进展及心血管疾病的预防和治疗效果。在缺血再灌注损伤诱导的急性肾损伤模型中,早期给予重组α-Klotho可预防急性肾损伤向慢性肾脏病进展并保护心脏免于重构;在单侧肾切除加对侧缺血再灌注损伤的慢性肾脏病模型中,晚期给药仍能有效改善肾功能并减轻心脏重构,但相关参数未完全恢复正常。重组α-Klotho蛋白安全有效,可能成为预防或延缓急性肾损伤向慢性肾脏病进展及尿毒症性心肌病的有前景的预防或治疗选择。

要点

  • 早期给予重组α-Klotho可预防缺血再灌注损伤诱导的急性肾损伤向慢性肾脏病进展。
  • 晚期给予重组α-Klotho可改善慢性肾脏病模型肾功能并减轻心脏重构,但未完全恢复正常。
  • 重组α-Klotho还可能减轻高磷饮食诱导的肾脏和心脏纤维化。

核心结论

  • 重组α-Klotho蛋白安全有效,可能成为预防或延缓急性肾损伤向慢性肾脏病进展及尿毒症性心肌病的有前景的预防或治疗选择。

研究设计与样本

  • 研究采用缺血再灌注损伤诱导的急性肾损伤模型,在肾损伤后第1天开始给予重组α-Klotho或溶媒并持续4天(慢性肾脏病预防方案)。
  • 慢性肾脏病模型由单侧肾切除加对侧缺血再灌注损伤建立,在损伤后4周开始晚期给予α-Klotho并持续12周(慢性肾脏病治疗方案)。

主要发现

  • 预防方案阻止了急性肾损伤向慢性肾脏病进展,并保护心脏免受急性肾损伤后模型中的心脏重构。
  • 外源性α-Klotho治疗的一个重要效应是在停止外源性α-Klotho治疗很久后恢复内源性α-Klotho水平。
  • 治疗方案仍有效改善慢性肾脏病中的肾功能并减轻心脏重构,尽管这些参数未完全恢复正常。
  • 给予α-Klotho还减轻了高磷饮食诱导的肾脏和心脏纤维化,并在无预先存在肾脏疾病的情况下改善了肾脏和心脏功能。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

α-Klotho is highly expressed in the kidney, and its extracellular domain is cleaved and released into the circulation. Chronic kidney disease (CKD) is a state of α-Klotho deficiency, which exerts multiple negative systemic effects on numerous organs including the cardiovascular system. Since acute kidney injury (AKI) greatly escalates the risk of CKD development, we explored the effect of α-Klotho on prevention and treatment on post-AKI to CKD progression and cardiovascular disease. Therein, ischemia reperfusion injury-induced AKI was followed by early administration of recombinant α-Klotho or vehicle starting one day and continued for four days after kidney injury (CKD prevention protocol). A CKD model was generated by unilateral nephrectomy plus contralateral ischemia reperfusion injury. Late administration of α-Klotho in this model was started four weeks after injury and sustained for 12 weeks (CKD treatment protocol). The prevention protocol precluded AKI to CKD progression and protected the heart from cardiac remodeling in the post-AKI model. One important effect of exogenous α-Klotho therapy was the restoration of endogenous α-Klotho levels long after the cessation of exogenous α-Klotho therapy. The treatment protocol still effectively improved renal function and attenuated cardiac remodeling in CKD, although these parameters did not completely return to normal. In addition, α-Klotho administration also attenuated high phosphate diet-induced renal and cardiac fibrosis, and improved renal and cardiac function in the absence of pre-existing renal disease. Thus, recombinant α-Klotho protein is safe and efficacious, and might be a promising prophylactic or therapeutic option for prevention or retardation of AKI-to-CKD progression and uremic cardiomyopathy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hu MC, Shi M, Gillings N, et al. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int. 2017. PMID: 28131398. doi:10.1016/j.kint.2016.10.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。